1 otherwise) and P is the time since vaccination, where time prior to vaccination is coded 0. The incidence and case fatality ratio of non-bacteraemic pneumonia are shown in The models were estimated using the maximum likelihood method, while exact confidence intervals were calculated using the standard chi-square intervals. We 
Appendix 3: Vaccine efficacy
Studies have shown that both antibody responses and opsonic activity in adults are as high or higher after vaccination with the pneumococcal conjugate vaccines than after vaccination with the 23-valent vaccination for the serotypes included in both vaccine formulations 3 . Also young age could be associated with a more pronounced immune response 4, 5 . Immunogenicity studies specifically focussing on high-risk individuals such as the frail elderly 6 , HIV-infected 7, 8 , and transplant recipients 9, 10 . Furthermore, this trial also evaluated the efficacy against the first episode if radiological confirmed alveolar consolidation (note that this is a measure of allcause pneumonia, not specific to the pneumococcus). In HIV infected children the point estimate was 13%(95% CI, -7-29), while in non infected children the efficacy was 20%. polysaccharide vaccine failed to demonstrate efficacy in a similar study. Also, the nine valent pneumococcal vaccine was shown to be effective in HIV-infected infants, although the vaccine efficacy was lower compared to those without HIV infection. It is however uncertain if these efficacy estimates will also apply for developed countries in which the invasive pneumococcal disease incidence is lower and HAART therapy is generally available 3 . Furthermore, it should be noted that these studies used multiple doses of the conjugated vaccine.
We performed a formal elicitation of expert opinions on vaccine related parameters to construct a probability distribution that represent the experts' knowledge and uncertainty.
The aim of the elicitation were to estimate efficacy and the level of waning immunity after vaccination with the13-valent pneumococcal conjugate vaccine in both high-risk immunocompromised and high-risk immunocompetent individuals aged less than 65 years or more than 65 years of age after one (one dose was used in the base case analysis) or two doses of the vaccine
The level of waning immunity was calculated by letting the experts estimate the vaccine efficacy during the first and third year after vaccination. Based on the difference in vaccine efficacy between these years the annual waning rate was calculated assuming an exponential decay of immunity.
A questionnaire covering these areas was designed using an iterative process involving trials on three test subjects and modifications to the questionnaire based on test subject feedback. We recruited five experts of the Pneumococcal Subcommittee of the Joint
Committee on Vaccination and Immunisation to undertake the elicitation process, as it is known that there is little additional benefit in combining expert judgments from more than 4 or 5 experts 17 . The experts were provided with background information on the question topics, the aims of the study, and the questionnaire by email.
Probability distributions were elicited using the quartile/probability technique, where each expert separately specified their median, lower, and upper quartile estimate 17 . After the initial elicitation, distributions were fitted to the estimations and experts were given the opportunity to revise their estimations if they thought this was necessary after comparing their estimate with those of the other experts. Subsequently, the obtained experts distributions were combined mathematically using the method of (linear) opinion pooling.
A beta distribution was chosen to fit to the experts' responses as this distribution is defined on the interval (0,1) and therefore suitable for quantifying uncertainty in probabilities. To obtain the distributions we used the Sheffield Elicitation Framework (SHELF, v2.0 www.tonyohagan.co.uk/shelf/).
The result of the elicitation can be found in Appendix 8: Age group specific incidence of invasive pneumococcal disease Appendix 8,  
